Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 45
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 15
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 14
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 14
Trop2-targeted therapies in solid tumors: advances and future directions
Xinlin Liu, Leina Ma, Jiyixuan Li, et al.
Theranostics (2024) Vol. 14, Iss. 9, pp. 3674-3692
Open Access | Times Cited: 10
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
Marjorie A. Shapiro
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 8
Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads
Meiyang Xi, Jingjing Zhu, Fengxia Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116709-116709
Closed Access | Times Cited: 8
Novel anticancer drug discovery efforts targeting glycosylation: the emergence of fluorinated monosaccharides analogs
Ana Costa, Andreia Teixeira, Celso A. Reis, et al.
Expert Opinion on Drug Discovery (2025), pp. 1-11
Closed Access | Times Cited: 1
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
Hitesh Vasiyani, Bhumika Wadhwa
Cellular Signalling (2025), pp. 111647-111647
Closed Access | Times Cited: 1
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Oncology: What You May Have Missed in 2024
Zainab Ali Amer Al Maqrashi, Sze Wah Samuel Chan, Zeba Siddiqui, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
HER2-low gastric cancer: is the subgroup targetable?
Keitaro Shimozaki, Shota Fukuoka, Akira Ooki, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103679-103679
Open Access | Times Cited: 7
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
Mariana Ribeiro Monteiro, Natália Abou Hala Nunes, Aumilto Junior, et al.
Breast Cancer Targets and Therapy (2024) Vol. Volume 16, pp. 51-70
Open Access | Times Cited: 6
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 6
Emerging paradigms and recent progress in targeting ErbB in cancers
Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 552-576
Open Access | Times Cited: 5
Tuneable redox-responsive albumin-hitchhiking drug delivery to tumours for cancer treatment
Shiwei Fu, Ajay Zheng, Lukun Wang, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 27, pp. 6563-6569
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Giovanni Tonon, Flavio Rizzolio, Fabiano Visentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8651-8651
Open Access | Times Cited: 5
A New Age of Drug Delivery: A Comparative Perspective of Ferritin–Drug Conjugates (FDCs) and Antibody–Drug Conjugates (ADCs)
Juanji Hong, Kang Li, Jiuyang He, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1142-1147
Closed Access | Times Cited: 5
Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development
Qi Ma, Puro Durga, Frederick X.C. Wang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104057-104057
Closed Access | Times Cited: 4
Resistance to antibody–drug conjugates: A review
Sijia Li, Xinyu Zhao, Kai Fu, et al.
Acta Pharmaceutica Sinica B (2025) Vol. 15, Iss. 2, pp. 737-756
Open Access
The novel strategy of Bispecific Antibody-Drug Conjugates (BsADCs) in Cancer Therapy
Zhengyu Li, Lu Yu, Lingshi Wang, et al.
Theoretical and Natural Science (2025) Vol. 75, Iss. 1, pp. 1-6
Closed Access
Page 1 - Next Page

Scroll to top